

Remarks

Claims 1-15, 18-19 and 37-59 were pending and subject to a Restriction Requirement. Claims 39, 42-49, 51 and 58-60 are canceled herein. Claims 37 and 57 are amended herein to be limited to the elected species, solely to advance prosecution.

Applicants expressly reserve the right to prosecute any deleted subject matter in a continuation or a divisional application.

New claims 61-64 are added herein. Support for new claims 61-64 can be found throughout the specification, such as on pages 40-53, 54 and 55.

Applicants believe no new matter is added herein. Reconsideration of the application is respectfully requested.

Telephone Conference

Applicants thank Examiner Le for the helpful telephone conference of April 25, 2008, wherein the restriction requirement was discussed. It is the Applicants understanding that the Examiner has reviewed the response submitted on November 9, 2007, and the Interview Summary and Exhibits submitted on December 18, 2007. The Examiner confirmed that the election of ODN7909 was acceptable, and requested that the claims be amended to refer to SEQ ID NO: 200 in order to advance prosecution. Additional amendments to the claims to advance prosecution, and the data presented in the Examples section, were briefly discussed.

Restriction Requirement

Applicants confirm the election of the claims of **Group II**, drawn to a method of enhancing the immunogenicity of a vaccine with traverse. Applicants submit that it would not be an undue burden on the Examiner to examine the claims of Group I with the claims of Group II, for the reasons of record.

Applicants further confirm the two elections of the species: (1) **SEQ ID NO: 200**, without traverse and (2) *Bacillus anthracis*, without traverse. As discussed with Examiner Le, the claims of Group II are amended herein to be limited to the elected species, solely to advance prosecution.

Claims 37-38, 40-42, 52-57 and 61-64 read on the elected invention.

Request for Interview


If any issues remain, Examiner Le is formally requested to contact the undersigned attorney prior to issuance of the next Office Action in order to arrange a telephonic interview. It is believed that a brief discussion of the merits of the present application may expedite prosecution. This request is being submitted under MPEP § 713.01, which indicates that an interview may be arranged in advance by a written request.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121